Free Trial
NASDAQ:NAGE

Niagen Bioscience (NAGE) Stock Price, News & Analysis

Niagen Bioscience logo
$9.16 -0.48 (-4.98%)
As of 08/5/2025 04:00 PM Eastern

About Niagen Bioscience Stock (NASDAQ:NAGE)

Key Stats

Today's Range
$9.08
$9.60
50-Day Range
$9.04
$14.41
52-Week Range
$2.62
$14.69
Volume
1.06 million shs
Average Volume
1.15 million shs
Market Capitalization
$721.53 million
P/E Ratio
53.88
Dividend Yield
N/A
Price Target
$13.22
Consensus Rating
Buy

Company Overview

Niagen Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

NAGE MarketRank™: 

Niagen Bioscience scored higher than 21% of companies evaluated by MarketBeat, and ranked 1668th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Niagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Niagen Bioscience has only been the subject of 2 research reports in the past 90 days.

  • Read more about Niagen Bioscience's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Niagen Bioscience is 53.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.78.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Niagen Bioscience is 53.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.91.

  • Price to Book Value per Share Ratio

    Niagen Bioscience has a P/B Ratio of 15.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NAGE.
  • Dividend Yield

    Niagen Bioscience does not currently pay a dividend.

  • Dividend Growth

    Niagen Bioscience does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NAGE.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 9% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Niagen Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.39% of the stock of Niagen Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 15.41% of the stock of Niagen Bioscience is held by institutions.

  • Read more about Niagen Bioscience's insider trading history.
Receive NAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter.

NAGE Stock News Headlines

Elon + Nvidia + ?????
Nvidia’s H100 chip has been the crown jewel of AI computing—until now. Elon Musk has just teamed up with Nvidia and a rising tech force to build the largest AI supercomputer ever attempted. The project? 100,000 of Nvidia’s most powerful chips. The opportunity? A backdoor for investors to align with this AI megatrend—before Wall Street catches on.
See More Headlines

NAGE Stock Analysis - Frequently Asked Questions

Niagen Bioscience's stock was trading at $5.48 at the beginning of 2025. Since then, NAGE stock has increased by 67.2% and is now trading at $9.16.

Niagen Bioscience, Inc. (NASDAQ:NAGE) posted its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.02. The firm earned $25.58 million during the quarter, compared to analyst estimates of $23.70 million. Niagen Bioscience had a trailing twelve-month return on equity of 19.06% and a net margin of 13.07%.
Read the conference call transcript
.

Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
10/31/2024
Today
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAGE
Previous Symbol
NASDAQ:NAGE
CIK
1386570
Web
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$8.00
Potential Upside/Downside
+44.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.17
Trailing P/E Ratio
53.88
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8.55 million
Net Margins
13.07%
Pretax Margin
13.51%
Return on Equity
19.06%
Return on Assets
12.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.66
Quick Ratio
3.12

Sales & Book Value

Annual Sales
$99.60 million
Price / Sales
7.24
Cash Flow
$0.06 per share
Price / Cash Flow
152.83
Book Value
$0.60 per share
Price / Book
15.27

Miscellaneous

Outstanding Shares
78,770,000
Free Float
71,373,000
Market Cap
$721.53 million
Optionable
N/A
Beta
2.12
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NAGE) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners